bromocriptine has been researched along with selegiline in 66 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (28.79) | 18.7374 |
| 1990's | 25 (37.88) | 18.2507 |
| 2000's | 16 (24.24) | 29.6817 |
| 2010's | 6 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Oliveri, V | 1 |
| Rinne, UK | 1 |
| Lander, CM; Lees, A; Stern, G | 1 |
| Yahr, MD | 1 |
| Lieberman, A | 1 |
| Levivier, M; Przedborski, S | 1 |
| Jacobs, MB; Varon, J | 1 |
| Ogawa, N | 1 |
| Calne, DB; Calne, S; Douglas, J; Postnikoff, D; Poulin, K; Ross, S; Tsui, JK; Woodward, W | 1 |
| LeWitt, PA | 1 |
| Birkmayer, JD; Birkmayer, W | 1 |
| Aminoff, MJ | 1 |
| Dubuis, R | 1 |
| Birkmayer, W | 1 |
| Calne, DB; Rinne, UK | 1 |
| Wirz, D | 1 |
| Hietala, J; Koulu, M; Scheinin, M; Syvälahti, E | 1 |
| Weiner, M | 1 |
| Birkmayer, W; Danielczyk, W; Jellinger, K; Koppel, H; Reynolds, GP; Riederer, P; Seemann, D; Ulm, G | 1 |
| Bihari, K; Csanda, E; Köves, A; Mogyorós, I; Takáts, A; Tárczy, M | 1 |
| Koulu, M; Lammintausta, R | 1 |
| Da Prada, M; Haefely, WE; Keller, HH; Kettler, R; Pieri, L | 1 |
| Agnoli, A; Baldassarre, M; D'Urso, R; Del Roscio, S; Falaschi, P; Frajese, G; Mearelli, S; Rocco, A; Ruggieri, S | 1 |
| Bushenbark, K; Esterlitz, J; Gauger, L; Hauser, RA; Hubble, J; Koller, W; Lilienfeld, D; Malapira, T; Olanow, CW | 1 |
| Eadie, MJ | 1 |
| Ludin, HP | 1 |
| Janjua, R; Roos, RA; van Kempen, GM | 1 |
| Danysz, W; Quack, G; Rogoz, Z; Skuza, G | 1 |
| Kintzer, PP; Peterson, ME | 1 |
| Eberli, F; Greminger, P; Schmid, PA; Speich, R; Suter, T | 1 |
| Dichgans, J; Klockgether, T | 1 |
| Curry, PT; Kitchin, RM; Motimaya, AM; Subramanya, KS | 1 |
| Lees, AJ | 1 |
| Calzetti, S; Cassio, A; Negrotti, A | 1 |
| Ahlskog, JE | 1 |
| Kishore, A; Snow, BJ | 1 |
| Dierks, T; Grosse, H; Kuhn, W; Müller, T; Rommelspacher, H | 1 |
| Montastruc, JL; Rascol, O; Senard, JM | 1 |
| McCallum, RW; Sarosiek, I; Shifflett, J; Soykan, I; Wooten, GF | 1 |
| Baudewig, J; Bruns, D; Paulus, W; Tergau, F; Ziemann, U | 1 |
| Brooks, DJ; Brunt, ER; Korczyn, AD; Poewe, WH; Rascol, O; Stocchi, F | 1 |
| Abrams, KR | 1 |
| Ben-Shlomo, Y; Churchyard, A; Head, J; Hurwitz, B; Lees, AJ; Ockelford, J; Overstall, P | 1 |
| Busenbark, K; Hauser, RA; Hubble, JP; Koller, WC; Malapira, T; Olanow, CW | 1 |
| Haapaniemi, TH; Kallio, MA; Korpelainen, JT; Myllylä, VV; Sotaniemi, KA; Suominen, K; Tolonen, U | 1 |
| Sternon, J; Supiot, F; Zegers de Beyl, D | 1 |
| Bizzarri, G; Calzetti, S; Negrotti, A | 1 |
| Haapaniemi, TH; Korpelainen, JT; Myllylä, VV; Sotaniemi, KA; Suominen, K; Tolonen, U | 1 |
| Ben-Shlomo, Y; Head, J; Katzenschlager, R; Lees, AJ | 1 |
| Okamoto, K; Tanaka, M | 1 |
| Mitsumoto, Y; Mori, A; Moriizumi, T; Nakai, M; Ohashi, S | 1 |
| Goetz, CG; Poewe, W; Rascol, O; Sampaio, C | 1 |
| Chan, PL; Holford, NH; Kieburtz, K; Nutt, JG; Shoulson, I | 1 |
| Hirohata, M; Ono, K; Yamada, M | 1 |
| Ben-Shlomo, Y; Evans, A; Head, J; Katzenschlager, R; Lees, AJ; Schrag, A | 1 |
| El Otmani, H; Fadel, H; Moutaouakil, F; Slassi, I | 1 |
| Schneemilch, C | 1 |
| Agúndez, JA; Alonso-Navarro, H; García-Martín, E; Jiménez-Jiménez, FJ | 1 |
| Ji, F; Jiang, R; Su, Z; Xue, R; Zhou, Y; Zhu, X; Zhuo, C | 1 |
19 review(s) available for bromocriptine and selegiline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Toward the discovery and development of effective modulators of α-synuclein amyloid aggregation.
Topics: alpha-Synuclein; Amyloidogenic Proteins; Drug Discovery; Humans; Protein Aggregation, Pathological; Structure-Activity Relationship | 2019 |
Recent advances in research on Parkinsonism.
Topics: Acetylcholinesterase; Adult; Apomorphine; Benserazide; Brain; Bromocriptine; Carbidopa; Dopa Decarboxylase; Dopamine; Drug Therapy, Combination; gamma-Aminobutyric Acid; Humans; Levodopa; Norepinephrine; Parkinson Disease; Selegiline; Serotonin; Substance P; Tyrosine 3-Monooxygenase | 1978 |
[Current therapeutic approach in Parkinson disease].
Topics: Antiparkinson Agents; Apomorphine; Bromocriptine; Fetal Tissue Transplantation; Humans; Levodopa; Mesencephalon; Parkinson Disease; Selegiline; Vitamin E | 1992 |
[New anti-parkinsonian drugs].
Topics: Antiparkinson Agents; Bromocriptine; Humans; Lisuride; Parkinson Disease; Pergolide; Picolinic Acids; Selegiline | 1991 |
New perspectives in the treatment of Parkinson's disease.
Topics: Bromocriptine; Dopamine; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Selegiline; Sincalide | 1986 |
'On-off' phenomenon: description, incidence and management.
Topics: Bromocriptine; Dose-Response Relationship, Drug; Humans; Levodopa; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Selegiline | 1987 |
Controversies in the management of Parkinson's disease.
Topics: Bromocriptine; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 1986 |
Update on the treatment of Parkinson's disease.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Synergism; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline; Time Factors | 1985 |
Update on antiparkinsonian agents.
Topics: Aged; Amantadine; Antiparkinson Agents; Blood-Brain Barrier; Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Gastrointestinal Diseases; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Receptors, Dopamine; Selegiline; Vascular Resistance | 1982 |
The pharmacology of Parkinson's disease: basic aspects and recent advances.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Brain; Bromocriptine; Carbidopa; Corpus Striatum; Dopamine; Ergolines; Humans; Kidney; Kinetics; Levodopa; Lisuride; Liver; Methyldopa; Norepinephrine; Parkinson Disease; Pergolide; Receptors, Dopamine; Selegiline; Serotonin; Stereotyped Behavior; Substantia Nigra; Tyramine | 1984 |
[Stage-adjusted treatment of idiopathic Parkinson syndrome].
Topics: Antiparkinson Agents; Bromocriptine; Carboxy-Lyases; Cholinergic Antagonists; Disability Evaluation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Selegiline | 1995 |
Medical treatment of pituitary-dependent hyperadrenocorticism in dogs.
Topics: Animals; Bromocriptine; Cushing Syndrome; Cyproheptadine; Dog Diseases; Dogs; Drug Administration Schedule; Ketoconazole; Mitotane; Selegiline | 1994 |
Treatment of early Parkinson's disease: are complicated strategies justified?
Topics: Animals; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Pergolide; Selegiline | 1996 |
Drug management of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Humans; Levodopa; Parkinson Disease; Selegiline; Trihexyphenidyl | 1996 |
New directions in the drug treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Bromocriptine; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline | 1996 |
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone | 2005 |
Anti-Parkinson's disease drugs and pharmacogenetic considerations.
Topics: Aryl Hydrocarbon Hydroxylases; Benzothiazoles; Benztropine; Bromocriptine; Cabergoline; Catechols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Ergolines; Genetic Markers; Humans; Indans; Indoles; Levodopa; Lisuride; Nitriles; Parkinson Disease; Pergolide; Pharmacogenetics; Pramipexole; Receptors, Dopamine D2; Receptors, Dopamine D3; Reproducibility of Results; Selegiline | 2013 |
Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis.
Topics: Bromocriptine; Cluster Analysis; Dopamine Agonists; Drug Therapy, Combination; Humans; Indoles; Levodopa; Network Meta-Analysis; Parkinson Disease; Picolinic Acids; Pramipexole; Selegiline; Tetrahydronaphthalenes; Thiophenes | 2017 |
16 trial(s) available for bromocriptine and selegiline
| Article | Year |
|---|---|
The effect of dietary protein on the efficacy of L-dopa: a double-blind study.
Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Clinical Trials as Topic; Dietary Proteins; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation; Selegiline | 1989 |
The effect of deprenyl and levodopa on the progression of Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Bromocriptine; Carbidopa; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Humans; Least-Squares Analysis; Levodopa; Male; Parkinson Disease; Prospective Studies; Selegiline; Statistics, Nonparametric; Treatment Outcome | 1995 |
Visual control of arm movement in Parkinson's disease.
Topics: Adult; Aged; Attention; Benserazide; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Orientation; Parkinson Disease; Psychomotor Performance; Reaction Time; Selegiline | 1994 |
Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.
Topics: Adult; Aged; Aged, 80 and over; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Selegiline; Treatment Outcome | 1993 |
Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
Topics: Antiparkinson Agents; Benserazide; Bromocriptine; Cause of Death; Disability Evaluation; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Proportional Hazards Models; Prospective Studies; Selegiline; Time Factors; Treatment Failure | 1995 |
L-deprenyl as an adjunct to low-dose bromocriptine in early Parkinson's disease: a short-term, double-blind, and prospective follow-up study.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Chemotherapy, Adjuvant; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Parkinson Disease; Placebos; Prospective Studies; Selegiline | 1995 |
Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Domperidone; Dopamine Antagonists; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Emptying; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Severity of Illness Index | 1997 |
Changes in human motor cortex excitability induced by dopaminergic and anti-dopaminergic drugs.
Topics: Administration, Oral; Adult; Analysis of Variance; Bromocriptine; Dopamine Agonists; Dopamine Antagonists; Electromyography; Evoked Potentials, Motor; Female; Haloperidol; Humans; Levodopa; Magnetics; Male; Motor Cortex; Physical Stimulation; Reference Values; Selegiline; Sulpiride | 1997 |
Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
Topics: Adult; Aged; Antiparkinson Agents; Bromocriptine; Confidence Intervals; Disease Progression; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indoles; Longitudinal Studies; Male; Middle Aged; Odds Ratio; Parkinson Disease; Regression Analysis; Selegiline; Severity of Illness Index; Treatment Outcome | 1998 |
Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry
Topics: Antiparkinson Agents; Bromocriptine; Cause of Death; Disabled Persons; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Parkinson Disease; Proportional Hazards Models; Selegiline; Survival Rate; Treatment Failure | 1998 |
Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Selegiline; Substance Withdrawal Syndrome | 2000 |
Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease.
Topics: Aged; Blood Pressure; Bromocriptine; Cardiovascular System; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline | 2000 |
Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Female; Humans; Male; Middle Aged; Motor Activity; Parkinson Disease; Selegiline; Severity of Illness Index; Single-Blind Method; Substance Withdrawal Syndrome | 2001 |
Suppressed sympathetic skin response in Parkinson disease.
Topics: Acoustic Stimulation; Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Electric Stimulation; Evoked Potentials; Evoked Potentials, Auditory; Female; Foot; Hand; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reaction Time; Reference Values; Selegiline; Skin; Sympathetic Nervous System | 2000 |
Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial.
Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Bromocriptine; Disability Evaluation; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Incidence; Levodopa; Male; Parkinson Disease; Selegiline; Treatment Outcome | 2001 |
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.
Topics: Antiparkinson Agents; Bromocriptine; Disability Evaluation; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Quality of Life; Selegiline | 2008 |
31 other study(ies) available for bromocriptine and selegiline
| Article | Year |
|---|---|
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations | 2002 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Oscillations in performance in levodopa-treated parkinsonians: treatment with bromocriptine and L-deprenyl.
Topics: Bromocriptine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1979 |
Overview of present day treatment of Parkinson's disease.
Topics: Adult; Aged; Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Receptors, Dopamine; Selegiline | 1978 |
Dopamine agonists used as monotherapy in de novo PD patients: comparisons with selegiline.
Topics: Bromocriptine; Clinical Trials as Topic; Dopamine Agents; Humans; Levodopa; Middle Aged; Parkinson Disease; Selegiline | 1992 |
Treating the progressive stages of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Combinations; Electroconvulsive Therapy; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Pergolide; Selegiline | 1991 |
Current and future approaches to therapy.
Topics: Antiparkinson Agents; Benserazide; Bromocriptine; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Parkinson Disease; Selegiline | 1987 |
Parkinson's disease in the elderly: current management strategies.
Topics: Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline | 1987 |
Milestones in the development of modern Parkinson therapy.
Topics: 2,3-Diketogulonic Acid; Alloxan; Behavior; Bromocriptine; Drug Combinations; Drug Therapy, Combination; Ferric Compounds; Humans; Levodopa; Neurology; Parkinson Disease; Selegiline; Tryptophan | 1987 |
Drugs for parkinsonism.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline | 1988 |
Neuroendocrine aspects in monitoring of dopaminergic drugs in man.
Topics: Apomorphine; Bromocriptine; Growth Hormone; Homovanillic Acid; Humans; Levodopa; Male; Metoclopramide; Monitoring, Physiologic; Neurosecretory Systems; Prolactin; Receptors, Dopamine; Schizophrenia; Selegiline; Time Factors | 1985 |
Combination treatment with selective monoamine oxidase inhibitors and dopaminergic agonists in Parkinson's disease: biochemical and clinical observations.
Topics: Bromocriptine; Dopamine; Drug Therapy, Combination; Humans; Lisuride; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Tranylcypromine | 1983 |
Adjuvant drugs in the treatment of on-off phenomena in Parkinson's disease.
Topics: Benzamides; Bromocriptine; Carboxy-Lyases; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Phenethylamines; Selegiline; Tiapamil Hydrochloride | 1984 |
Human growth hormone and dopaminergic drugs, with special reference to deprenyl (selegiline): a summary of studies on volunteers.
Topics: Apomorphine; Bromocriptine; Dopamine; gamma-Aminobutyric Acid; Growth Hormone; Humans; Levodopa; Phenethylamines; Receptors, Dopamine; Selegiline; Synapses | 1983 |
Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study.
Topics: Aged; Apomorphine; Benserazide; Bromocriptine; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Nomifensine; Parkinson Disease; Prolactin; Receptors, Dopamine; Selegiline; Tremor | 1980 |
Treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Pergolide; Prognosis; Selegiline | 1995 |
Effect of disease and drug treatment on blood serotonin and monoamine oxidase B activity in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Blood Platelets; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Selegiline; Serotonin; Treatment Outcome | 1995 |
Memantine, amantadine, and L-deprenyl potentiate the action of L-dopa in monoamine-depleted rats.
Topics: Amantadine; Animals; Bromocriptine; Dopamine; Drug Synergism; Levodopa; Male; Memantine; Motor Activity; N-Methylaspartate; Parkinson Disease; Rats; Rats, Wistar; Selegiline | 1994 |
[Bromocriptine-induced pleuropneumopathy].
Topics: Benserazide; Biperiden; Bromocriptine; Humans; Levodopa; Lung Diseases; Male; Middle Aged; Parkinson Disease; Pleural Effusion; Pulmonary Atelectasis; Pulmonary Fibrosis; Radiography; Selegiline; Time Factors | 1994 |
Assessment of genotoxicity of two anti-parkinsonian drugs (selegiline hydrochloride and bromocriptine mesylate) in vivo in mouse bone marrow cells.
Topics: Analysis of Variance; Animals; Bone Marrow; Bone Marrow Cells; Bromocriptine; Cell Survival; Erythrocytes; Female; Injections, Intraperitoneal; Male; Mice; Micronucleus Tests; Mutagens; Selegiline | 1993 |
Plasma levels of the beta-carbolines harman and norharman in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbolines; Female; Humans; Levodopa; Male; Middle Aged; Mitochondria; Parkinson Disease; Selegiline | 1995 |
Monitoring randomised controlled trials. Parkinson's disease trial illustrates the dangers of stopping early.
Topics: Antiparkinson Agents; Bromocriptine; Decision Making; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline | 1998 |
[Dopaminergic agonists in the treatment of Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Apomorphine; Benzothiazoles; Biological Availability; Bromocriptine; Catechols; Dopamine Agonists; Drug Combinations; Drug Hypersensitivity; Humans; Hypotension, Orthostatic; Indoles; Levodopa; Metabolic Clearance Rate; Nitriles; Parkinson Disease; Pergolide; Pramipexole; Selegiline; Thiazoles | 2000 |
[Therapy for patients with early-stage Parkinson's disease].
Topics: Amantadine; Animals; Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Practice Guidelines as Topic; Selegiline; Trihexyphenidyl | 2003 |
Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Behavior, Animal; Blotting, Western; Brain Chemistry; Bromocriptine; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Drug Interactions; Hindlimb Suspension; Immobility Response, Tonic; Immunohistochemistry; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Motor Activity; Nerve Tissue Proteins; Selegiline; Time Factors; Tyrosine 3-Monooxygenase | 2005 |
Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.
Topics: Algorithms; Antiparkinson Agents; Bayes Theorem; Bromocriptine; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Models, Biological; Parkinson Disease; Pergolide; Randomized Controlled Trials as Topic; Selegiline; Treatment Outcome | 2006 |
Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro.
Topics: alpha-Synuclein; Antiparkinson Agents; Bromocriptine; Dopamine; Dose-Response Relationship, Drug; In Vitro Techniques; Molecular Structure; Neurofibrillary Tangles; Pergolide; Polymers; Selegiline; Trihexyphenidyl | 2007 |
[Severe apathy following head injury: improvement with Selegiline treatment].
Topics: Adolescent; Adult; Behavior; Bromocriptine; Craniocerebral Trauma; Dopamine Agonists; Emotions; Glasgow Coma Scale; Humans; Magnetic Resonance Imaging; Male; Mental Disorders; Monoamine Oxidase Inhibitors; Motivation; Prefrontal Cortex; Radiography; Selegiline | 2009 |
[General anaesthesia for neurological diseases].
Topics: Anesthesia, General; Anesthetics, Inhalation; Anesthetics, Intravenous; Autonomic Nervous System; Brain; Bromocriptine; Dopamine Agonists; Humans; Intubation; Levodopa; Monoamine Oxidase Inhibitors; Muscle Relaxants, Central; Nervous System Diseases; Neurodegenerative Diseases; Neurosurgery; Parkinson Disease; Piperidines; Premedication; Preoperative Care; Propofol; Remifentanil; Selegiline; Stereotaxic Techniques; Syndrome | 2010 |